Cyclin E2

A novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle

Nathalie Lauper, Andreas R P Beck, Sandrine Cariou, Larry Richman, Kay Hofmann, Walter Reith, Joyce M Slingerland, Bruno Amati

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

We report here the cloning and characterization of human and mouse cyclin E2, which define a new subfamily within the vertebrate E-type cyclins, while all previously identified family-members belong to the cyclin E1 subfamily. Cyclin E2/CKD2 and cyclin E/CDK2 complexes phosphorylate histone H1 in vitro with similar specific activities and both are inhibited by p27(Kip1). Cyclin E2 mRNA levels in human cells oscillate throughout the cell cycle and peak at the G1/S boundary, in parallel with the cyclin E mRNA. In cells, cyclin E2 is complexed with CDK2, p27 and p21. Like cyclin E, cyclin E2 is an unstable protein in vivo and is stabilized by proteasome inhibitors. Cyclin E2-associated kinase activity rises in late G1 and peaks very close to cyclin E activity. In two malignantly transformed cell lines, cyclin E2 activity is sustained throughout S phase, while cyclin E activity has already declined and cyclin A activity is only beginning to rise. We speculate that cyclin E2 is not simply redundant with cyclin E, but may regulate distinct rate-limiting pathway(s) in G1-S control.

Original languageEnglish
Pages (from-to)2637-2643
Number of pages7
JournalOncogene
Volume17
Issue number20
StatePublished - Nov 19 1998
Externally publishedYes

Fingerprint

Cyclins
G1 Phase
S Phase
Cyclin E
Cell Cycle
Cyclin A
Messenger RNA
Transformed Cell Line
Proteasome Inhibitors
Histones
Vertebrates
Organism Cloning
Phosphotransferases

Keywords

  • CDK2
  • Cyclin E
  • Cyclin E2
  • p27(Kip1)

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Lauper, N., Beck, A. R. P., Cariou, S., Richman, L., Hofmann, K., Reith, W., ... Amati, B. (1998). Cyclin E2: A novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle. Oncogene, 17(20), 2637-2643.

Cyclin E2 : A novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle. / Lauper, Nathalie; Beck, Andreas R P; Cariou, Sandrine; Richman, Larry; Hofmann, Kay; Reith, Walter; Slingerland, Joyce M; Amati, Bruno.

In: Oncogene, Vol. 17, No. 20, 19.11.1998, p. 2637-2643.

Research output: Contribution to journalArticle

Lauper, N, Beck, ARP, Cariou, S, Richman, L, Hofmann, K, Reith, W, Slingerland, JM & Amati, B 1998, 'Cyclin E2: A novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle', Oncogene, vol. 17, no. 20, pp. 2637-2643.
Lauper N, Beck ARP, Cariou S, Richman L, Hofmann K, Reith W et al. Cyclin E2: A novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle. Oncogene. 1998 Nov 19;17(20):2637-2643.
Lauper, Nathalie ; Beck, Andreas R P ; Cariou, Sandrine ; Richman, Larry ; Hofmann, Kay ; Reith, Walter ; Slingerland, Joyce M ; Amati, Bruno. / Cyclin E2 : A novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle. In: Oncogene. 1998 ; Vol. 17, No. 20. pp. 2637-2643.
@article{27573cac9d994fb5b61967d36e7b61b9,
title = "Cyclin E2: A novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle",
abstract = "We report here the cloning and characterization of human and mouse cyclin E2, which define a new subfamily within the vertebrate E-type cyclins, while all previously identified family-members belong to the cyclin E1 subfamily. Cyclin E2/CKD2 and cyclin E/CDK2 complexes phosphorylate histone H1 in vitro with similar specific activities and both are inhibited by p27(Kip1). Cyclin E2 mRNA levels in human cells oscillate throughout the cell cycle and peak at the G1/S boundary, in parallel with the cyclin E mRNA. In cells, cyclin E2 is complexed with CDK2, p27 and p21. Like cyclin E, cyclin E2 is an unstable protein in vivo and is stabilized by proteasome inhibitors. Cyclin E2-associated kinase activity rises in late G1 and peaks very close to cyclin E activity. In two malignantly transformed cell lines, cyclin E2 activity is sustained throughout S phase, while cyclin E activity has already declined and cyclin A activity is only beginning to rise. We speculate that cyclin E2 is not simply redundant with cyclin E, but may regulate distinct rate-limiting pathway(s) in G1-S control.",
keywords = "CDK2, Cyclin E, Cyclin E2, p27(Kip1)",
author = "Nathalie Lauper and Beck, {Andreas R P} and Sandrine Cariou and Larry Richman and Kay Hofmann and Walter Reith and Slingerland, {Joyce M} and Bruno Amati",
year = "1998",
month = "11",
day = "19",
language = "English",
volume = "17",
pages = "2637--2643",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "20",

}

TY - JOUR

T1 - Cyclin E2

T2 - A novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle

AU - Lauper, Nathalie

AU - Beck, Andreas R P

AU - Cariou, Sandrine

AU - Richman, Larry

AU - Hofmann, Kay

AU - Reith, Walter

AU - Slingerland, Joyce M

AU - Amati, Bruno

PY - 1998/11/19

Y1 - 1998/11/19

N2 - We report here the cloning and characterization of human and mouse cyclin E2, which define a new subfamily within the vertebrate E-type cyclins, while all previously identified family-members belong to the cyclin E1 subfamily. Cyclin E2/CKD2 and cyclin E/CDK2 complexes phosphorylate histone H1 in vitro with similar specific activities and both are inhibited by p27(Kip1). Cyclin E2 mRNA levels in human cells oscillate throughout the cell cycle and peak at the G1/S boundary, in parallel with the cyclin E mRNA. In cells, cyclin E2 is complexed with CDK2, p27 and p21. Like cyclin E, cyclin E2 is an unstable protein in vivo and is stabilized by proteasome inhibitors. Cyclin E2-associated kinase activity rises in late G1 and peaks very close to cyclin E activity. In two malignantly transformed cell lines, cyclin E2 activity is sustained throughout S phase, while cyclin E activity has already declined and cyclin A activity is only beginning to rise. We speculate that cyclin E2 is not simply redundant with cyclin E, but may regulate distinct rate-limiting pathway(s) in G1-S control.

AB - We report here the cloning and characterization of human and mouse cyclin E2, which define a new subfamily within the vertebrate E-type cyclins, while all previously identified family-members belong to the cyclin E1 subfamily. Cyclin E2/CKD2 and cyclin E/CDK2 complexes phosphorylate histone H1 in vitro with similar specific activities and both are inhibited by p27(Kip1). Cyclin E2 mRNA levels in human cells oscillate throughout the cell cycle and peak at the G1/S boundary, in parallel with the cyclin E mRNA. In cells, cyclin E2 is complexed with CDK2, p27 and p21. Like cyclin E, cyclin E2 is an unstable protein in vivo and is stabilized by proteasome inhibitors. Cyclin E2-associated kinase activity rises in late G1 and peaks very close to cyclin E activity. In two malignantly transformed cell lines, cyclin E2 activity is sustained throughout S phase, while cyclin E activity has already declined and cyclin A activity is only beginning to rise. We speculate that cyclin E2 is not simply redundant with cyclin E, but may regulate distinct rate-limiting pathway(s) in G1-S control.

KW - CDK2

KW - Cyclin E

KW - Cyclin E2

KW - p27(Kip1)

UR - http://www.scopus.com/inward/record.url?scp=0032547954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032547954&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 2637

EP - 2643

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 20

ER -